Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
2.140
-0.060 (-2.73%)
Nov 21, 2024, 12:26 PM EST - Market open
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $84.00K in the quarter ending May 31, 2024, with 8.10% growth. This brings the company's revenue in the last twelve months to $411.02K, up 34.05% year-over-year. In the fiscal year ending August 31, 2023, Lexaria Bioscience had annual revenue of $226.21K, down -11.43%.
Revenue (ttm)
$411.02K
Revenue Growth
+34.05%
P/S Ratio
56.11
Revenue / Employee
$82,204
Employees
5
Market Cap
37.35M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
Aug 31, 2019 | 222.61K | -210.68K | -48.62% |
Aug 31, 2018 | Pro | Pro | Pro |
Aug 31, 2017 | Pro | Pro | Pro |
Aug 31, 2016 | Pro | Pro | Pro |
Aug 31, 2015 | Pro | Pro | Pro |
Aug 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Outset Medical | 114.73M |
Beyond Air | 2.34M |
Lumos Pharma | 2.21M |
Eterna Therapeutics | 598.00K |
Incannex Healthcare | 86.00K |
LEXX News
- 1 day ago - ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study - Accesswire
- 7 days ago - Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - Accesswire
- 8 days ago - Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Accesswire
- 14 days ago - Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments - Accesswire
- 4 weeks ago - Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study - Accesswire
- 4 weeks ago - Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study - Accesswire
- 5 weeks ago - Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 5 weeks ago - Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire